Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion InfusionsDHA:ORIONINFU 75 Cash Ratio is 0.03 as of Mar. 2026, which is at its 10-year median of 0.03. GuruFocus rates DHA:ORIONINFU with a GF Score™ of 75/100 and a GF Value™ of BDT313.77 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 936 Drug Manufacturers companies, Orion Infusions ranks worse than 93.91% on this metric.
Orion Infusions has a Cash Ratio of 0.03. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Orion Infusions's Cash Ratio or its related term are showing as below:
DHA:ORIONINFU'
s Cash Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.03 Max: 0.09
Current: 0.03
During the past 13 years, Orion Infusions's highest Cash Ratio was 0.09. The lowest was 0.01. And the median was 0.03.
DHA:ORIONINFU's Cash Ratio is ranked worse than 93.91% of 936
companies
in the Drug Manufacturers industry
Industry Median: 0.59
vs DHA:ORIONINFU: 0.03
Orion Infusions (DHA:ORIONINFU) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Orion Infusions Cash Ratio Related Terms
Orion Infusions Cash Ratio Historical Data
* Premium members only.
The historical data trend for Orion Infusions's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONINFU vs ZTS, UTHR, VTRS: Cash Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Orion Infusions's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Infusions Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orion Infusions's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Orion Infusions's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Infusions (DHA:ORIONINFU) has a Cash Ratio of 0.03 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Orion Infusions and its competitors. This is near median its historical median of 0.03. Over the past decade, Orion Infusions' Cash Ratio has ranged from 0.01 to 0.09. According to the industry distribution chart, Orion Infusions ranks #879 out of 936 companies in the Drug Manufacturers industry, placing it in the top 93.9%.
Is Orion Infusions' Cash Ratio too high?
Orion Infusions' current Cash Ratio of 0.03 is near median its 10-year median of 0.03. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.09. The Drug Manufacturers industry median Cash Ratio is 0.59. Orion Infusions' value of 0.03 is 94.9% below this industry median. Based on the distribution chart, Orion Infusions ranks #879 out of 936 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Orion Infusions has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orion Infusions' Cash Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orion Infusions ranks #879 out of 936 companies for Cash Ratio. This places Orion Infusions in the lower half of its industry. The industry median Cash Ratio is 0.59. Orion Infusions' value of 0.03 is 94.9% below this benchmark. Historically, Orion Infusions' own Cash Ratio has ranged from 0.01 to 0.09 over the past decade. While the company's 10-year median is 0.03 vs. the industry median of 0.59, Orion Infusions has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.59, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Infusions's current Cash Ratio of 0.03 is 94.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Orion Infusions and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Infusions's current Cash Ratio is 0.03, which is near median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Infusions stock overvalued right now?
Based on GuruFocus' analysis, Orion Infusions (DHA:ORIONINFU) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT313.77, compared to a current price of BDT242.70 — trading 22.7% below its estimated fair value. The current Cash Ratio is 0.03, which is near median its 10-year median of 0.03 and 94.9% below the Drug Manufacturers industry median of 0.59. Orion Infusions' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Orion Infusions (DHA:ORIONINFU), the current Cash Ratio is 0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Infusions (DHA:ORIONINFU) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Infusions stock appears to be undervalued.
The current stock price of BDT242.70 is trading 22.7% below its estimated GF Value™ of BDT313.77.
GuruFocus considers Orion Infusions to be Modestly Undervalued.
Key valuation signals for DHA:ORIONINFU:
Cash Ratio: 0.03 (near median its 10-year median of 0.03)
GF Value™: BDT313.77 vs. price of BDT242.70 (22.7% below fair value)
Industry Position: 94.9% below the Drug Manufacturers median (#879 of 936)
No single metric tells the full story. See the DHA:ORIONINFU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Infusions Ltd is a pharmaceutical company engaged in the production of various types of intravenous fluids, rehydration solutions, electrolyte solutions, and solutions for acidosis, as well as Ranitidine I.V. infusion and anti-microbial products such as Ciprofloxacin I.V. and Metronidazole I.V. The Company's products include Dextrolac, Dextropac, Dextrosal, Dianak, Electro Dex, Fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the Group operates across several sectors, including pharma and healthcare, power and energy, infrastructure development, real estate, cosmetics and toiletries, consumer products, textiles and garments, and home appliances. Geographically, the Company operates in Bangladesh.
75GF Score
Get the complete analysis for DHA:ORIONINFU
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONINFU has been successfully added to your 
